Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.

Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY

Open source

DOI: 10.1093/neuonc/nox151
Published: 2018 Jan 22
Container: Neuro-oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/neuonc/nox151,
  title = {Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.},
  author = {Cloughesy TF and Drappatz J and de Groot J and Prados MD and Reardon DA and Schiff D and Chamberlain M and Mikkelsen T and Desjardins A and Ping J and Holland J and Weitzman R and Wen PY},
  year = {2018},
  journal = {Neuro-oncology},
  doi = {10.1093/neuonc/nox151},
  url = {https://doi.org/10.1093/neuonc/nox151}
}

RIS

TY  - JOUR
TI  - Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.
AU  - Cloughesy TF
AU  - Drappatz J
AU  - de Groot J
AU  - Prados MD
AU  - Reardon DA
AU  - Schiff D
AU  - Chamberlain M
AU  - Mikkelsen T
AU  - Desjardins A
AU  - Ping J
AU  - Holland J
AU  - Weitzman R
AU  - Wen PY
PY  - 2018
JO  - Neuro-oncology
DO  - 10.1093/neuonc/nox151
UR  - https://doi.org/10.1093/neuonc/nox151
ER  -

APA

TF, C., J, D., J, D. G., MD, P., DA, R., D, S., M, C., T, M., A, D., J, P., J, H., R, W., & PY, W. (2018). Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.. Neuro-oncology. https://doi.org/10.1093/neuonc/nox151

Source records

pubmed · retrieved 2026-09-27T09:54:19.529Z